Medical Xpress

NOVEMBER 15, 2022

In a new 'Ideas and Opinions,' authors from Johns Hopkins Bloomberg School of Public Health analyze California's newly announced effort to manufacture insulin for its residents. The commentary is published in Annals of Internal Medicine.

Insulin 98

Insulin Manufacturing Medicine Drugs 98

BioPharma Reporter

APRIL 17, 2023

The South Korean company is set to create a new facility in West Virginia to house insulin manufacturing and to deliver its insulin products in the country.

Insulin 52

Insulin Manufacturing Production Regulation 52

pharmaphorum

JANUARY 13, 2023

The ‘big three’ insulin producers Novo Nordisk, Eli Lilly, and Sanofi are being sued by the state of California for allegedly working together to set artificially inflated prices for their products. The suit follows legal action over insulin pricing taken by other states, including Arkansas , Kansas, Mississippi, and Minnesota.

Insulin 105

Insulin Manufacturing Production Pharmacy 105

Bio Pharma Dive

AUGUST 16, 2023

The new coupons include some of the most commonly prescribed diabetes drugs from Eli Lilly, Novo Nordisk and Sanofi.

Insulin 130

Insulin Pharmacy Manufacturing Drugs 130

STAT News

APRIL 21, 2023

WASHINGTON — Amid a scramble to assemble a health care policy package in the Senate, a pair of key senators have significantly changed a proposal to cap insulin costs. The new legislation by Senate Diabetes Caucus co-chairs Sens. Jeanne Shaheen (D-N.H.)

Insulin 98

Insulin Packaging Packaging Pharmacy 98

STAT News

JANUARY 20, 2023

In an attempt to tackle the root causes of inflated insulin prices, the state of California filed a lawsuit last week accusing drug manufacturers and pharmacy benefit managers of artificially and illegally jacking up the price of insulin. The sausage-making of how insulin is priced is not for the faint of heart.

Insulin 105

Insulin Pharmacy Manufacturing Drugs 105

STAT News

MARCH 9, 2023

Now that Eli Lilly is cutting prices on some of its insulin products, Sen. This week, he introduced a bill that would place a $20 cap on all insulin, a move designed to drastically lower costs for millions of Americans. Bernie Sanders (I-Vt.) is seeking to build on that momentum. Continue to STAT+ to read the full story…

Insulin 98

Insulin Manufacturing Production Drugs 98

Drug Channels

SEPTEMBER 15, 2023

Nicole summarizes MMIT’s research on payers’ views of two crucial market changes: (1) the Inflation Reduction Act of 2022’s requirement to cap insulin prices at $35 for Medicare beneficiaries, and (2) manufacturers’ reduction in list prices for certain insulin products.

Insulin 72

Insulin Manufacturing Drugs Production 72

STAT News

OCTOBER 6, 2022

The three companies that dominate the global market for insulin have launched various programs to expand the reach of their medicines in dozens of low and middle-income countries — but their efforts remain patchy and equitable access consequently remains out of reach, according to a new analysis.

Insulin 111

Insulin Regulation Manufacturing Medicine 111

STAT News

MARCH 16, 2023

Following the lead of its rivals, Sanofi will cut the price of its most widely prescribed insulin in the U.S. The change comes after Eli Lilly and then Novo Nordisk announced plans this month to reduce list prices for some of their own insulin products by similar amounts. The moves will go into effect on Jan.

Insulin 98

Insulin Manufacturing Production Marketing 98

BioSpace

DECEMBER 28, 2020

rBIO launched last week with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs.

Insulin 102

Insulin Manufacturing Drugs 102

Fierce Pharma

NOVEMBER 8, 2023

While Novo Nordisk struggles with manufacturing concerns and patient coverage on its long-acting insulin Levemir, Bayer missed a primary endpoint in a confirmatory trial for its P13K inhibitor Aliq | While Bayer's P13K Aliqopa couldn't prove its worth in a confirmatory trial, Novo's Levemir faced manufacturing issues and troubles with (..)

Insulin 52

Insulin Manufacturing Marketing Trials 52

STAT News

MARCH 17, 2023

Enjoy, and see you soon … Following the lead of its rivals, Sanofi will cut the price of its most widely prescribed insulin in the U.S. The three companies are the largest manufacturers of insulin and collectively hold a dominant 80% share of the market. Continue to STAT+ to read the full story…

Insulin 98

Insulin Research Drugs Manufacturing 98

pharmaphorum

MARCH 2, 2022

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time. Smart insulin pens are expected to drive the insulin pen market from $13.8

Insulin 52

Insulin Marketing Doctors Doctor 52

XTalks

SEPTEMBER 23, 2020

Being hailed as the world’s shortest and thinnest needle for insulin injection, Droplet Micron has recently been introduced into the pen needle market by HTL (High Tech Lab)-STREFA, Inc. These are important feature innovations for those that depend on insulin injections. The new and innovative needle measures at just 34G x 3.5mm.

Insulin 98

Insulin Marketing Drug Delivery Compliance 98

Outsourcing Pharma

JULY 18, 2023

Convatec Group, a medical products and technologies company focused on chronic conditions, has partnered with Tandem Diabetes Care on a new five-inch infusion set for Tandem Mobi, the worldâs smallest durable automated insulin delivery system.

Insulin 72

Insulin Manufacturing Production Regulation 72

Drug Channels

JANUARY 26, 2021

A new Senate report reveals unprecedented information about PBMs, manufacturers, and the gross-to-net bubble for insulin. Plus, a 2021 update to my all-time favorite chart. P.S. Join the nearly 11,000 followers of my daily links to neat stuff at @DrugChannels on Twitter.

Insulin 52

Insulin Manufacturing Drugs 52

Pharmaceutical Technology

FEBRUARY 24, 2023

(LAI-287 + semaglutide) overview A fixed dose combination of GLP-1 analogue semaglutide and LAI-287, long-acting basal insulin is under development for the treatment of type 2 diabetes. The drug candidate is administered as an subcutaneous formulation.The combination acts by targeting GLP-1R and insulin receptor.

Insulin 182

Insulin Hormones Drugs Clinical Trials 182

The Pharma Data

SEPTEMBER 30, 2021

Lilly’s Insulin Lispro Injection, 100 units/mL — first introduced at half the list price of branded Humalog® (insulin lispro injection, 100 units/mL) in 2019 — will now have a 70 percent lower list price than Humalog U-100 starting January 1, 2022 Insulin Lispro Injection can be ordered through all U.S.

Insulin 52

Insulin Pharmacy Branding Medicine 52

Outsourcing Pharma

JULY 18, 2023

Convatec Group, a medical products and technologies company focused on chronic conditions, has partnered with Tandem Diabetes Care on a new five-inch infusion set for Tandem Mobi, the worldâs smallest durable automated insulin delivery system.

Insulin 52

Insulin Manufacturing Production Regulation 52

XTalks

FEBRUARY 24, 2021

The injection experience is an often-overlooked aspect in insulin administration. For many daily insulin users, the experience is an important one, as it is directly related to quality of life and medication compliance. Related: Droplet Micron Insulin Needle Offers Innovation in Crowded Diabetes Supply Market.

Insulin 64

Insulin Production Drug Delivery Marketing 64

XTalks

MARCH 15, 2024

The drugs include Lilly’s newly approved GLP-1 obesity drug Zepbound (tirzepatide), around a dozen of the company’s insulins and migraine drug Emgality (galcanezumab). It is estimated that more than 8 million Americans rely on insulin products to manage their diabetes.

Pharmacy 111

Pharmacy Drugs Insulin Branding 111

Pharmaceutical Technology

JULY 12, 2022

VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy of Vertex for T1D. Through the acquisition, Vertex plans to advance its potentially curative VX-880 programmes in T1D.

Gene Therapy 276

Gene Therapy Insulin Manufacturing Clinical Trials 276

The Pharma Data

FEBRUARY 25, 2021

and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc’s software into Lilly’s connected insulin solutions, currently in development. Lilly will commercialize the pen platform, which will include the new app and Lilly’s connected insulin pen solutions.

Insulin 40

Insulin Medicine Hormones Development 40

STAT News

MARCH 9, 2023

WASHINGTON — President Biden made lowering drug prices a key part of his budget with proposals to expand Medicare drug price negotiation, squeeze more rebates out of drug companies, and lower the cost of insulin for everyone with insurance. The request made Thursday also details a $7.2

Cosmetics 98

Cosmetics Drugs Insulin Regulation 98

pharmaphorum

NOVEMBER 8, 2022

The Tempo system brings together a pre-filled insulin pen, the TempoSmart app and a recently-approved Smart Button device that stores and transfers insulin dose-related data from the pen, and can link with compatible devices. Smart insulin pens are expected to drive the insulin pen market from $13.8

Insulin 64

Insulin Marketing Branding Manufacturing 64

The Pharma Data

JUNE 28, 2021

In honor of the 100th anniversary of the discovery of insulin, Eli Lilly and Company (NYSE: LLY) today launched the Leonard Award to recognize diverse champions dedicated to advancing diabetes management through innovative thinking and novel approaches. Nominations are being accepted now until August 31, 2021 at Lilly.com/LeonardAward.

Insulin 52

Insulin Nurses Hormones Medicine 52

Drug Channels

AUGUST 11, 2020

Time for our annual update on pricing at five of the largest pharmaceutical manufacturers—Eli Lilly, Janssen, Merck, Novartis, and Sanofi. As the companies’ insulin data illustrate below, the bubble raises costs for patients who are not always benefiting from lower net selling prices. You can find links to each company’s data below.

Insulin 52

Insulin Branding Drugs Manufacturing 52

The Pharma Data

MAY 6, 2021

The Tempo Pen is a modified version of Lilly ‘s existing prefilled, disposable insulin pen to which the Tempo Smart Button – pending CE (Conformité Européenne or European Conformity) marking – attaches. Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin. About DexCom Inc.

Insulin 52

Insulin Medicine Production Hormones 52

Pharmaceutical Technology

APRIL 10, 2023

Under the deal, Cipla will be responsible for the manufacturing and marketing of Galvus and its combination brands from 1 January 2026. Furthermore, Galvus can be used in combination with other medicinal products such as insulin when unable to offer adequate glycaemic control.

Branding 130

Branding Insulin Drugs Production 130

Roots Analysis

NOVEMBER 27, 2023

billion) in expanding its manufacturing facility in Chartres, France. The move follows a recent USD 6 billion investment by the company to expand manufacturing capabilities at its primary site in Kalundborg, Denmark. billion (USD 2.3 With this additional EUR 2.1 Eli Lilly’s recent USD 2.5 The post Novo Nordisk Invested EUR 2.1

Manufacturing 40

Manufacturing Sales Production Marketing 40

Pharmaceutical Technology

MARCH 1, 2023

In the last few years, there have been growing calls to onshore the manufacturing of certain pharma products, including active pharmaceutical ingredients (API), to ensure a smooth supply and to minimise shortages in the European Union (EU).

Production 130

Production Insulin FDA Approval Pharma Production 130

BioTech 365

OCTOBER 29, 2020

–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it is being honored by two Massachusetts agencies for the Company’s contributions … Continue reading →

Insulin 40

Insulin Manufacturing 40

XTalks

FEBRUARY 8, 2024

In 2022, Januvia was flagged for nitrosamine contamination , a potential carcinogen commonly produced as a byproduct during drug manufacturing. In its 2022 financial report, Sanofi reported that sales of the long-acting insulin dropped 27.6 In its 2022 financial report, Sanofi reported that sales of the long-acting insulin dropped 27.6

Sales 52

Sales Insulin FDA Approval Drugs 52

Velocity Clinical Research

JUNE 27, 2023

Rosenstock is the lead investigator for Novo Nordisk’s ONWARDS 1 program exploring the first investigational once-weekly insulin. “In In ONWARDS 1, insulin icodec allowed people to spend significantly more Time in Range, with comparable Time below Range vs. once-daily basal insulin glargine U100,” said Dr. Rosenstock. “A

Insulin 52

Insulin Trials Hormones Clinical Trials 52

BioSpace

SEPTEMBER 29, 2020

Gavin Newsom signed Senate Bill 852 into law on Monday, paving the way for California to manufacture cheaper versions of insulin and other drugs that have been in short supply in recent years. California Gov.

Insulin 64

Insulin Marketing Manufacturing Drugs 64

Pharmaceutical Technology

JUNE 29, 2022

For hundreds of years, we have found myriad uses for microbial enzymes in manufacturing – from food, drink, and household products to a range of industrial applications. The enzymes must be manufactured under cGMP conditions – completely free of animal-derived ingredients.”. Developing best-in-class speciality enzymes.

Drugs 295

Drugs Gene Therapy Manufacturing Production 295